{
    "nct_id": "NCT06047080",
    "official_title": "A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma",
    "inclusion_criteria": "* Previously untreated participants with CD20-positive LBCL\n* Ability to provide tumor tissue\n* International prognostic index (IPI) score 2-5\n* Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2\n* At least one bi-dimensionally measurable lesion, defined as > 1.5 cm in its longest dimension as measured by CT or MRI\n* Left ventricular ejection fraction (LVEF) >/=50% on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)\n* Adequate hematologic function\n* Negative HIV test at screening with exceptions as defined by the protocol\n* Negative SARS-CoV-2 antigen or PCR test\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Contraindication to any of the individual components of Pola-R-CHP or glofitamab, including prior receipt of anthracyclines, or history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, or known sensitivity or allergy to murine products\n* Prior solid organ transplantation\n* Participants receiving systemic immunosuppressive agent such as, but not limited to cyclosporin, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 4 weeks prior to first dose of study treatment\n* Current Grade > 1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease\n* History of indolent lymphoma (e.g., Follicular Lymphoma, Marginal Zone Lymphoma, Waldenstrom macroglobulinemia)\n* Current diagnosis of the following: Follicular lymphoma grade 3B; transformations of indolent B-cell lymphomas (e.g., de novo transformed follicular lymphoma); mediastinal grey zone lymphoma; primary mediastinal (thymic) large B-cell lymphoma; Burkitt lymphoma; primary large B-cell lymphoma of immune-privileged sites (encompassing primary diffuse large B-cell lymphoma of the CNS, primary large B-cell lymphoma of the vitreoretina and primary large B-cell lymphoma of the testis); primary effusion DLBCL; and primary cutaneous DLBCL, leg type\n* Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma\n* Prior treatment with systemic immunotherapeutic agents\n* Prior use of any monoclonal antibody for the purposes of treating cancer within 3 months of the start of Cycle 1\n* Any investigational therapy for the purposes of treating cancer within 28 days prior to the start of Cycle 1\n* Prior radiotherapy to the mediastinal/pericardial region\n* Prior therapy for LBCL, with the exception of corticosteriods\n* Corticosteroid use > 30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control\n* History of other malignant or non-malignant diseases that could affect compliance with the protocol or interpretation of results\n* Significant or extensive history of cardiovascular disease\n* Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis\n* Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Known or suspected chronic active Epstein-Barr viral infection\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)\n* Active autoimmune disease requiring treatment\n* Clinically significant liver disease\n* Live, attenuated vaccine within 4 weeks before study treatment infusion on Day 1 of Cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study. Live vaccines during the study and until participants B cells recover are prohibited\n* Any active infection within 7 days prior to Cycle 1 Day 1 that would impact participant safety\n* Suspected active or latent tuberculosis\n* Positive test results for chronic hepatitis B infection, hepatitis C, or the human T-lymphotropic virus type 1 (HTLV-1)\n* History of progressive multifocal leukoencephalopathy",
    "miscellaneous_criteria": ""
}